Udveje Behandling Aps: Financial statements 2024
CVR: 40518916
Source: annual report 2024, Danish Business Authority
01/10/2023 – 30/09/2024
Udveje Behandling Aps (CVR 40518916) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 4,473,923 and a net result of DKK 541,297 compared with DKK 710,064 the year before. That is a decrease of 8.2% compared with the year before. Equity in the 2024 report amounted to DKK 960,872. The solvency ratio was 42.7%.
- Gross Profit
- DKK 4,473,923
- Profit/Loss
- DKK 541,297
- Equity
- DKK 960,872
- Total Assets
- DKK 2,251,528
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | 4.5M | 541K | 961K | - |
| 2023 | - | 4.9M | 710K | 775K | 7 |
| 2022 | - | 2M | 237K | 445K | - |
| 2021 | - | 1.1M | 222K | 208K | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Udveje Behandling Aps has published its annual report for 2023. Gross profit came to DKK 4,873,418, and the net result was DKK 710,064.
About Udveje Behandling Aps
Udveje Behandling Aps is a Danish company of the type Anpartsselskab based in Store Merløse, founded in 2019. The company is registered under the industry Traditionelle, komplementære og alternative behandlingsformer. The company was previously named Udveje ApS. The management consists of John Kastrup. The board consists of Rolf Nolsøe Bau (chair), Chit Calopez Lodberg, Claus Christiansen and Kirsten Benediktson. The company is owned by UDVEJE Holding ApS. The company has 17 employees (2026). In 2025, the company reported a gross profit of DKK 4,937,535 and a net result of DKK 64,996 compared with DKK 541,297 the year before. Equity in the 2025 report amounted to DKK 675,868.